No. Bristol-Myers Squibb Company (BMY) does not pass our halal screen, as of 18 November 2026. It fails on interest-bearing debt.
NYSE · Healthcare · Screened 18 November 2026. Its verdict has not changed since our public ledger began on 24 September 2026.
| Business activity | Pass | From the 10-K (2025): The company's revenue is entirely derived from the sale of innovative medicines and related alliance/royalty income, all of which are permissible. |
| Interest-bearing debt | Fail | Total debt is 36.0% of market cap (limit 30%). |
| Cash & interest-bearing securities | Pass | Cash & securities are 8.8% of market cap (limit 30%). |
| Non-permissible income (< 5%) | Review | Interest income isn't reported for this company, so this can't be read automatically. Verify in the financial notes. |
No changes recorded since 24 September 2026.
See every change across all stocks on the public verdict ledger.
No. Bristol-Myers Squibb Company (BMY) does not pass our halal screen, as of 18 November 2026. It fails on interest-bearing debt.
Two of the tests compare debt and cash with the company's market value. When the share price moves, those ratios move, so a stock can cross the 30% line without the business changing at all. Its verdict has not changed since our public ledger began on 24 September 2026.
We use an AAOIFI-style screen: the business itself must be permissible, interest-bearing debt and interest-bearing cash must each be under 30% of market value, and non-permissible income must be under 5% of revenue. It is an automated estimate, not a fatwa.
Free halal check for US, Australian, Malaysian and Singapore stocks.
Check a stockAAOIFI-style screen by Barakah Profits. Automated estimate, not a fatwa. Always confirm with a qualified scholar before investing. Financial data provided by Twelve Data. This is general information, not financial advice.